Effect of Schisandra chinensis extract and Ginkgo biloba extract on the pharmacokinetics of talinolol in healthy volunteers

Xenobiotica

Volumn 39, Issue 3, 2009, Pages 249-254

  Fan, L ^a   Mao, X Q ^a   Tao, G Y ^a   Wang, G ^a   Jiang, F ^b   Chen, Y ^a   Li, Q ^a   Zhang, W ^a   Lei, H P ^a   Hu, D L ^a   Huang, Y F ^a   Wang, D ^a   Zhou, H H ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Inje University College of Medicine   (South Korea)

^c NONE

Author keywords

Ginkgo biloba extract; Herb drug interaction; Inhibition; P glycoprotein; Pharmacokinetics; Schisandra chinensis extract; Talinolol

Indexed keywords

GINKGO BILOBA EXTRACT; GLYCOPROTEIN P; SCHISANDRA CHINENSIS EXTRACT; TALINOLOL; PLANT EXTRACT; PROPANOLAMINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG POTENTIATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; BLOOD; CHEMISTRY; CHINA; DRUG ANTAGONISM; GINKGO BILOBA; ORAL DRUG ADMINISTRATION; SCHISANDRACEAE;

GINKGO BILOBA; SCHISANDRA CHINENSIS;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHINA; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GINKGO BILOBA; HUMANS; MALE; P-GLYCOPROTEIN; PLANT EXTRACTS; PROPANOLAMINES; SCHISANDRA;

EID: 66149157856     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.1080/00498250802687657     Document Type: Article

References (29)

1. Bernsdorf A, May K, Kuhnert-Keil C, Möritz KU, Kroemer HK, Siegmund W. (2003). Expression of P-glycoprotein and MRP2-deficient rats (GY/TR-). Naunyn-Schmiedeberg's Archiv Pharmacol 367:R110. [abstract]
2. Bogman K, Zysset Y, Degen L, Hopfgartner G, Gutmann H, Alsenz J, Drewe J. (2005). P-glycoprotein and surfactants: effect on intestinal talinolol absorption. Clin Pharmacol Ther 77:24-32.
3. Chen CC, Shen CC, Shih YZ, Pan TM. (1994). 6-O-benzoylgomisin O. A new lignan from the fruits of Schizandra chinensis. J Natural Prod 57:1164-1165.
4. Diamond BJ, Shiflett SC, Feiwel N, Matheis RJ, Noskin O, Richards JA, Schoenberger NE. (2000). Ginkgo biloba extract: mechanisms and clinical indications. Archiv Phys Med Rehabilit 81:668-678.
5. Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, Dazert P, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer HK, Siegmund W. (2004). Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 76:192-200.
6. Haenisch S, May K, Wegner D, Caliebe A, Cascorbi I, Siegmund W. (2008). Influence of genetic polymorphisms on intestinal expression and rifampicin-type induction of ABCC2 and on bioavailability of talinolol. Pharmacogenet Genom 18:357-365.
7. Ikeya Y, Miki E, Okada M, Mitsuhashi H, Chai JG. (1990). Benzoylgomisin Q and benzoylgomisin P, two new lignans from Schisandra sphenanthera Rehd. et Wils. Chem Pharmaceut Bull 38:1408-1411.
8. Ikeya Y, Taguchi H, Mitsuhashi H, Takeda S, Kase Y, Aburada M. (1988). A lignan from Schizandra chinensis. Phytochemistry 27:569-574.
9. Ikeya Y, Taguchi H, Yosioka I, Iitaka Y, Kobayashi H. (1979). The constituents of Schizandra chinensis Baill. II. The structure of a new lignan, gomisin D. Chem Pharmaceut Bull 27:1395-1401. (Pubitemid 9237110)
10. Ikeya Y, Taguchi H, Yosioka I, Kobayashi H. (1979). The constituents of Schizandra chinensis Baill. I. Isolation and structure determination of five new lignans, gomisin A, B, C, F and G, and the absolute structure of schizandrin. Chem Pharmaceut Bull 27:1383-1394. (Pubitemid 9237109)
11. Joshi BS, Kaul PN. (2001). Alternative medicine: herbal drugs and their critical appraisal, I. Prog Drug Res 56:1-76.
12. Juan H, Terhaag B, Cong Z, Bi-Kui Z, Rong-Hua Z, Feng W, Fen-Li S, Juan S, Jing T, Wen-Xing P. (2007). Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol 63:663-668.
13. Nabekura T, Yamaki T, Ueno K, Kitagawa S. (2008). Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol 62:867-873.
14. Oertel R, Richter K, Trausch B, Berndt A, Gramatte T, Kirch W. (1994). Elucidation of the structure of talinolol metabolites in man. Determination of talinolol and hydroxylated talinolol metabolites in urine and analysis of talinolol in serum. J Chromatograph B Biomed Appl 660:353-363.
15. Pan Q, Wang T, Lu Q, Hu X, Schisandrin B. (2005). A novel inhibitor of P-glycoprotein. Biochem Biophys Res Comm 335:406-411.
16. Schwarz UI, Dresser GK, Oertel R, Kim RB. (2001). Talinolol-verapamil interaction is not solely due to P-glycoprotein inhibition. Clin Pharmacol Ther 69:P85 [Abstract].
17. Schwarz UI, Gramatté T, Krappweis J, Berndt A, Oertel R, von Richter O, Kirch W. (1999). Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. Clin Pharmacol Ther 65:283-290.
18. Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. (2007). Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther 81:669-678.
19. Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W. (2005). Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther 77:291-301.
20. Siegmund W, Altmannsberger S, Paneitz A, Hecker U, Zschiesche M, Franke G, Meng W, Warzok R, Schroeder E, Sperker B, Terhaag B, Cascorbi I, Kroemer HK. (2002). Effect of levothyroxine administration on intestinal P-glycoprotein expression: consequences for drug disposition. Clin Pharmacol Ther 72:256-264.
21. Spahn-Langguth H, Baktir G, Radschuweit A, Okyar A, Terhaag B, Ader P, Hanafy A, Langguth P. (1998). P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound. Int J Clin Pharmacol Ther 36:16-24.
22. Sun M, Xu X, Lu Q, Pan Q, Hu X, Schisandrin B. (2007). A dual inhibitor of P-glycoprotein and multidrug resistance-associated protein 1. Cancer Lett 246:300-307.
23. Terhaag B, Palm U, Sahre H, Richter K, Oertel R. (1992). Interaction of talinolol and sulfasalazine in the human gastrointestinal tract. Eur J Clin Pharmacol 42:461-462.
24. Wan CK, Zhu GY, Shen XL, Chattopadhyay A, Dey S, Fong WF. (2006). Gomisin A alters substrate interaction and reverses P-glycoprotein-mediated multidrug resistance in HepG2-DR cells. Biochem Pharmacol 72:824-837.
25. Wang Y, Cao J, Zeng S. (2005). Involvement of P-glycoprotein in regulating cellular levels of Ginkgo flavonols: quercetin, kaempferol, and isorhamnetin. J Pharm Pharmacol 57:751-758.
26. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. (2000). Oral bioavailability of digoxin is enhanced by talinolol: evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68:6-12.
27. Westphal K, Weinbrenner A, Zschiesche M, Franke G, Knoke M, Oertel R, Fritz P, von Richter O, Warzok R, Hachenberg T, Kauffmann HM, Schrenk D, Terhaag B, Kroemer HK, Siegmund W. (2000). Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 68:345-355.
28. Wetterich U, Spahn-Langguth H, Mutschler E, Terhaag B, Rosch W, Langguth P. (1996). Evidence for intestinal secretion as an additional clearance pathway of talinolol enantiomers: concentration- and dose-dependent absorption in vitro and in vivo. Pharmaceut Res 13:514-522.
29. Xin HW, Wu XC, Li Q, Yu AR, Zhu M, Shen Y, Su D, Xiong L. (2007). Effects of Schisandra sphenanthera extract on the pharmacokinetics of tacrolimus in healthy volunteers. Br J Clin Pharmacol 64:469-475.